Benzinga · Sep 25, 2026
HC Wainwright & Co. Reiterates Buy on Telix Pharmaceuticals, Maintains $20 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Telix Pharmaceuticals (NASDAQ:TLX) with a Buy and maintains $20 price target.
TL
NASDAQ · TLX
Telix Pharmaceuticals Limited
Healthcare · Biotechnology
$10.55
Down-$0.17 (-1.59%)
Updated Oct 4, 2026, 12:04 AM
SID Score
5.2/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 3.18B
- P/E ratio
- 133.11
- Dividend yield
- 0.00%
- 52-week range
- $7.20 – $13.11
- Volume
- 299.61K
- Avg. volume
- 128.55K
Price performance · TLX
TLX price history
1M range · 19 trading sessions · Daily adjusted prices
Prices through Oct 2, 2026
TLX closed at $10.55 after 19 trading sessions, down 11.94% for the selected period.
- Last close
- $10.55
- Period change
- -11.94%
- Period low
- $10.55
- Period high
- $12.83
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 2, 2026 | $10.64 | $10.64 | $10.45 | $10.55 | 299.61K |
| Oct 1, 2026 | $10.90 | $10.94 | $10.72 | $10.72 | 201.81K |
| Sep 30, 2026 | $11.23 | $11.23 | $10.93 | $10.97 | 344.24K |
| Sep 29, 2026 | $11.64 | $11.64 | $11.23 | $11.34 | 428.31K |
| Sep 28, 2026 | $11.44 | $11.69 | $11.35 | $11.62 | 851K |
| Sep 25, 2026 | $11.30 | $11.45 | $11.275 | $11.45 | 409.2K |
| Sep 24, 2026 | $11.29 | $11.38 | $11.11 | $11.31 | 830.29K |
| Sep 23, 2026 | $11.41 | $11.4479 | $11.20 | $11.27 | 464.89K |
| Sep 22, 2026 | $11.93 | $12.10 | $11.83 | $11.95 | 613.71K |
| Sep 21, 2026 | $11.24 | $11.60 | $10.76 | $11.31 | 865.93K |
| Sep 18, 2026 | $12.73 | $12.80 | $12.55 | $12.59 | 187.4K |
| Sep 17, 2026 | $12.45 | $12.7196 | $12.375 | $12.505 | 412.91K |
| Sep 16, 2026 | $12.22 | $12.22 | $11.625 | $11.83 | 642.23K |
| Sep 15, 2026 | $12.62 | $13.1098 | $12.59 | $12.83 | 1.08M |
| Sep 14, 2026 | $12.20 | $12.23 | $11.67 | $11.78 | 630.49K |
| Sep 11, 2026 | $11.75 | $11.75 | $11.1962 | $11.29 | 415.34K |
| Sep 10, 2026 | $12.10 | $12.20 | $11.88 | $11.90 | 337.79K |
| Sep 9, 2026 | $12.085 | $12.48 | $11.965 | $12.34 | 548.31K |
| Sep 8, 2026 | $12.07 | $12.21 | $11.98 | $11.98 | 336.39K |
Latest TLX news
The latest Smart Investors Daily articles mentioning TLX.
Stock researchCompany · Overview
Company
Market Activity
Research & News
TLX research
Overview
Company profile and research snapshot.
Company profile
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $20.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 25, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 23, 2026 | Wedbush | Outperform | — |
| Sep 15, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 14, 2026 | Wedbush | Outperform | — |
| Sep 2, 2026 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 23, 2026
Telix (ASX:TLX) Shares Could Be 42% Undervalued Following Its ITM Deal
Telix Pharmaceuticals has delivered a very strong 185.1% share price gain over the past five years, yet the latest acquisition plans and product approvals leave a clear question about whether that journey is still backed by its cash flows. With the stock now trading around A$16.08 after a weaker recent patch, investors are increasingly focused on what the underlying cash generation can reasonably support. That 185.1% return over five years puts real weight on whether Telix’s current...
Yahoo · Sep 23, 2026
Telix Pharmaceuticals (ASX:TLX) ITM Deal Puts Valuation Back In Focus
Telix Pharmaceuticals (ASX:TLX) has moved to lead a merger with ITM Isotope Technologies Munich SE, a radioisotope producer and radiopharmaceutical developer, in a transaction valued at up to A$2.35b. Telix Pharmaceuticals shares trade at A$16.08 after a sharp 1 day share price decline of 4.23% and a 7 day share price fall of 4.68% following the merger announcement. However, the year to date share price return of 41.55% and 5 year total shareholder return of 185.11% suggest longer term...
Benzinga · Sep 23, 2026
Wedbush Reiterates Outperform on Telix Pharmaceuticals, Maintains $22 Price Target
Wedbush analyst David Nierengarten reiterates Telix Pharmaceuticals (NASDAQ:TLX) with a Outperform and maintains $22 price target.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
